Tags

Type your tag names separated by a space and hit enter

Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen.
Vaccine. 2006 May 08; 24(19):4116-21.V

Abstract

Currently, two intradermal (ID) regimens for rabies post-exposure prophylaxis (PEP) are recommended by WHO and used in countries where approved by national authorities: the Thai Red Cross (TRC) two-site ID regimen and the eight-site ID regimen. Besides these WHO recommended schedules, a new economical four-site ID regimen was evaluated that reduces the cost of PEP by up to 80%, when compared with the standard intramuscular Essen regimen, reduces the number of visits required for the patients when compared with the TRC regimen, and is more convenient than the eight-site regimen. To determine the immunogenicity of the ID four-site PEP regimen (4-0-2-0-1-1), 180 healthy volunteers were randomized to receive 0.1 mL volumes of PCECV or PVRV administered ID over both left and right shoulders and both deltoid regions on day 0, both deltoid regions on day 7 and over one deltoid region on days 30 and 90. Regardless of the vaccine, every subject developed rabies virus neutralizing antibody (RVNA) titers above 0.5 IU/mL by day 14, as determined by rapid fluorescent focus inhibition test (RFFIT) using a homologous test system. Two weeks after the last dose of vaccine, RVNA titers were all above 0.5 IU/mL (day 104). Geometric mean titers were similar throughout the study period. Both vaccines were well tolerated. These results demonstrate that a new four-site ID PEP regimen is a cost-effective and convenient alternative to IM (Essen or Zagreb) or ID (TRC or eight-site) regimens, especially using a 1 mL vial of vaccine (PCECV).

Authors+Show Affiliations

Infectious Diseases and Microbiology Department, Vilnius University, Vilnius, Lithuania.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase III
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16545510

Citation

Ambrozaitis, Arvydas, et al. "Rabies Post-exposure Prophylaxis Vaccination With Purified Chick Embryo Cell Vaccine (PCECV) and Purified Vero Cell Rabies Vaccine (PVRV) in a Four-site Intradermal Schedule (4-0-2-0-1-1): an Immunogenic, Cost-effective and Practical Regimen." Vaccine, vol. 24, no. 19, 2006, pp. 4116-21.
Ambrozaitis A, Laiskonis A, Balciuniene L, et al. Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen. Vaccine. 2006;24(19):4116-21.
Ambrozaitis, A., Laiskonis, A., Balciuniene, L., Banzhoff, A., & Malerczyk, C. (2006). Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen. Vaccine, 24(19), 4116-21.
Ambrozaitis A, et al. Rabies Post-exposure Prophylaxis Vaccination With Purified Chick Embryo Cell Vaccine (PCECV) and Purified Vero Cell Rabies Vaccine (PVRV) in a Four-site Intradermal Schedule (4-0-2-0-1-1): an Immunogenic, Cost-effective and Practical Regimen. Vaccine. 2006 May 8;24(19):4116-21. PubMed PMID: 16545510.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen. AU - Ambrozaitis,Arvydas, AU - Laiskonis,Alvydas, AU - Balciuniene,Ligita, AU - Banzhoff,Angelika, AU - Malerczyk,Claudius, Y1 - 2006/02/28/ PY - 2005/10/24/received PY - 2006/02/13/revised PY - 2006/02/15/accepted PY - 2006/3/21/pubmed PY - 2006/8/26/medline PY - 2006/3/21/entrez SP - 4116 EP - 21 JF - Vaccine JO - Vaccine VL - 24 IS - 19 N2 - Currently, two intradermal (ID) regimens for rabies post-exposure prophylaxis (PEP) are recommended by WHO and used in countries where approved by national authorities: the Thai Red Cross (TRC) two-site ID regimen and the eight-site ID regimen. Besides these WHO recommended schedules, a new economical four-site ID regimen was evaluated that reduces the cost of PEP by up to 80%, when compared with the standard intramuscular Essen regimen, reduces the number of visits required for the patients when compared with the TRC regimen, and is more convenient than the eight-site regimen. To determine the immunogenicity of the ID four-site PEP regimen (4-0-2-0-1-1), 180 healthy volunteers were randomized to receive 0.1 mL volumes of PCECV or PVRV administered ID over both left and right shoulders and both deltoid regions on day 0, both deltoid regions on day 7 and over one deltoid region on days 30 and 90. Regardless of the vaccine, every subject developed rabies virus neutralizing antibody (RVNA) titers above 0.5 IU/mL by day 14, as determined by rapid fluorescent focus inhibition test (RFFIT) using a homologous test system. Two weeks after the last dose of vaccine, RVNA titers were all above 0.5 IU/mL (day 104). Geometric mean titers were similar throughout the study period. Both vaccines were well tolerated. These results demonstrate that a new four-site ID PEP regimen is a cost-effective and convenient alternative to IM (Essen or Zagreb) or ID (TRC or eight-site) regimens, especially using a 1 mL vial of vaccine (PCECV). SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/16545510/Rabies_post_exposure_prophylaxis_vaccination_with_purified_chick_embryo_cell_vaccine__PCECV__and_purified_Vero_cell_rabies_vaccine__PVRV__in_a_four_site_intradermal_schedule__4_0_2_0_1_1_:_an_immunogenic_cost_effective_and_practical_regimen_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(06)00218-0 DB - PRIME DP - Unbound Medicine ER -